Review
Biotechnology & Applied Microbiology
Taylor P. Berke, Simon H. Slight, Salman M. Hyder
Summary: The tumor suppressor protein p53 plays a crucial role in preventing cancer. Mutations in the p53 gene are associated with various cancers. Reactivating mutant p53 protein and controlling the progression of triple-negative breast cancer (TNBC) through the use of non-toxic natural compounds is recommended.
ONCOTARGETS AND THERAPY
(2022)
Review
Oncology
Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai, Mingyu Chen
Summary: TP53 is a critical tumor-suppressor gene commonly mutated in human cancers, with potential oncogenic properties when mutated. Treatments for cancers with mutant p53 involve targeting mutant p53 directly, restoring wild-type functions, and exploring synthetic lethal interactions with mutant p53 for therapeutic benefits. Additionally, disrupting noncoding RNA networks may have potential synthetic lethal effects in cancers with p53 mutations.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Cell Biology
Che-Pei Kung, Jason D. Weber
Summary: The relationship between P53, MDM2, and ARF plays a crucial role in tumor suppression mechanisms, but our understanding of this relationship needs to be updated in order to develop more effective cancer treatments.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Shengliang Zhang, Lanlan Zhou, Wafik S. El-Deiry
Summary: This study identified an inducible ROS-ERK2-MDM2 axis as a vulnerability for mutant p53 degradation in cancer cells, which can be targeted by small-molecule compounds for cancer therapy.
MOLECULAR CANCER RESEARCH
(2022)
Article
Oncology
Maryam Rasouli, Sara Khakshournia, Omid Vakili, Sanaz Dastghaib, Atefeh Seghatoleslam, Sayed Mohammad Shafiee
Summary: Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths worldwide. UBE2Q1, a newly identified ubiquitin-conjugating enzyme, is significantly expressed in colorectal tumors. The study suggests that UBE2Q1 may contribute to CRC progression by modulating the levels of p53 protein. Experimental results show that transfection of UBE2Q1 leads to a significant decrease in p53 protein levels in SW480 cells, while the change in p53 protein levels is not significant in LS180 cells. This indicates that UBE2Q1 may promote CRC progression by interacting with and degrading p53 protein.
Article
Oncology
Mohammad B. Uddin, Kartik R. Roy, Ronald A. Hill, Sagor C. Roy, Xin Gu, Li Li, Qian-Jin Zhang, Zongbing You, Yong-Yu Liu
Summary: Mutant p53 suppresses NK cell activation, allowing breast cancer cells to escape immune attack. Wildtype p53 is necessary for NK cell recognition and elimination of cancer cells, while p53 mutations impair NK cell responses.
EXPERIMENTAL CELL RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Mehregan Babamohamadi, Esmaeil Babaei, Burhan Ahmed Salih, Mahshid Babamohammadi, Hewa Jalal Azeez, Goran Othman
Summary: The p53 protein is a tumor suppressor that regulates various cellular processes and is closely related to cancer development. It can be used as a biomarker for tumor progression and a target for cancer treatment. This review discusses the contribution of wild-type p53 loss of function, its role in ferroptosis and targeted therapy, and challenges and solutions in p53-related drug delivery systems.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Review
Genetics & Heredity
Pavana Lakshmi Vaddavalli, Bjoern Schumacher
Summary: The TP53 gene is the most frequently mutated gene in human cancers, and p53 plays a crucial role in responding to DNA damage. Dysfunctional p53 leads to continued proliferation of cells with damaged genome, promoting malignant transformation. Recent research has shed light on the complexity of p53 regulation in the DNA damage response, as well as its systemic effects influenced by non-cell-autonomous signaling mechanisms. There have also been advancements in therapeutic targeting of p53.
TRENDS IN GENETICS
(2022)
Article
Biochemistry & Molecular Biology
Pingzhao Zhang, Kun Gao, Liang Zhang, Huiru Sun, Xiaying Zhao, Yajuan Liu, Zeheng Lv, Qing Shi, Yingji Chen, Dongyue Jiao, Yao Li, Wei Gu, Chenji Wang
Summary: This study demonstrates the important role of CRL2-KLHDC3 E3 ubiquitin ligase complex in regulating the stability of p14(ARF) protein, with KLHDC3 promoting ubiquitin-proteasomal degradation of p14(ARF) to suppress ferroptosis and support tumor growth. The findings suggest that overexpression of KLHDC3 likely contributes to cancer progression by suppressing the p14(ARF)-NRF2-SLC7A11 regulatory pathway.
CELL DEATH AND DIFFERENTIATION
(2022)
Review
Biochemistry & Molecular Biology
Cheng Zou, Ying Wan, Lingjing He, Jin Hai Zheng, Yang Mei, Junfeng Shi, Min Zhang, Zhiqiang Dong, Dingxiao Zhang
Summary: RBPs are widely dysregulated in numerous human cancers, and RBM38, as a well-studied RBP, frequently plays a tumor-suppressive role in multiple human cancer types. By uncovering a spectrum of transcripts bound by RBM38, the diversity in its mechanisms of action in distinct biological contexts can be revealed, indicating the possibility of targeting RBM38 and its related pathways as therapeutic strategies against cancer.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Review
Cell Biology
Cen Zhang, Juan Liu, Jianming Wang, Tianliang Zhang, Dandan Xu, Wenwei Hu, Zhaohui Feng
Summary: Hypoxia is crucial in solid tumors, with HIF and p53 signaling pathways playing key roles in regulating cellular responses to hypoxia. The interplay between hypoxia and p53 pathways can impact cancer progression, with p53 regulating hypoxia and HIF signaling in various ways, while mutant p53 can promote cancer progression through interaction with hypoxia and HIF signaling.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Yuan Yin, Zhiyuan Jiang, Jiamei Fu, Yang Li, Chao Fang, Xiaonan Yin, Ye Chen, Na Chen, Junshu Li, Yanhong Ji, Xiaolan Su, Meng Qiu, Wei Huang, Bo Zhang, Hongxin Deng, Lei Dai
Summary: The study reveals the expression and function of SLC5 family members in colorectal cancer, showing that downregulation of SLC5A7 correlates with CRC staging and prognosis response. Overexpression of SLC5A7 inhibits CRC growth by promoting p53 protein expression, suggesting a potential therapeutic target for CRC.
Article
Oncology
Apisada Jiso, Philipp Demuth, Madeleine Bachowsky, Manuel Haas, Nina Seiwert, Daniel Heylmann, Birgit Rasenberger, Markus Christmann, Lea Dietrich, Thomas Brunner, Riyanti, Till F. Schaeberle, Anuchit Plubrukarn, Joerg Fahrer
Summary: Merosesquiterpenes show promise as potential therapeutic agents for colorectal cancer, as they induce DNA damage, trigger apoptosis, and exhibit cytotoxic activity against CRC cell lines and tumor organoids. Their efficacy is observed in both wild-type and mutant p53 CRC cells, making them a potential candidate for CRC chemotherapy.
Review
Biochemistry & Molecular Biology
Zilu Wang, Andreas Strasser, Gemma L. Kelly
Summary: Mutations in the TP53 gene are common in human cancers and can lead to tumor development. Mutant TP53 proteins often have high expression levels in malignant cells and can impair the response of these cells to anti-cancer drugs. These mutant proteins have been found to affect cellular pathways through loss-of-function, dominant negative effects, and gain-of-function mechanisms. The sustained proliferation and survival of malignant cells rely on the gain-of-function effects of mutant TP53 proteins, suggesting that targeting these proteins could have therapeutic potential.
CELL DEATH AND DIFFERENTIATION
(2022)
Review
Genetics & Heredity
Marco Corazzari, Licio Collavin
Summary: Cancer cells within tumor masses are exposed to various stressors and accumulate mutations, contributing to their adaptation to chronic stress. One extreme outcome of chronic stress is ferroptosis, a form of cell death mediated by lipid peroxidation. The tumor suppressor p53 and its cancer-related mutants play a role in modulating ferroptosis, potentially impacting cancer treatment options.
FRONTIERS IN GENETICS
(2023)